Replies to post #247519 on Avid Bioservices Inc (CDMO)

[md1225]

Thanks CJ it literally gives me chills to watch that video with Dr Massague and think MSK chose Peregrine to work with! Literally unbelievable were Peregrine is today phase III fully enrolled anyday, look ins any week, we as long investors have an unbelievable opportunity to invest at prices were pphm is at today. To think the head of MSK chose to work with Peregrine and now six months later after seeing Bavituximab first hand in the lab again Dr Massague chooses Peregrines Bavituximab to be featured at a conference were he the head of MSK is chairing.

Wow is all I can say!

As James keeps saying no way is Gilead or Astra Zenica or Bristol going to wait for more data for a pissing match.

It's all coming down to the art of the deal!

Chris LaCoursiere

http://seekingalpha.com/article/3657006-peregrine-pharmaceuticals-the-art-of-the-deal

[biopharm]

Great post CJ! Now it all starts to unravel on why MSK Memorial Sloan Kettering has chosen to work with Peregrine Pharmaceuticals....

Jan7-10 2016: “AACR's The Function of Tumor Microenvironment in Cancer Progression Conf.”, SanDiego
“This AACR Special Conference will focus on discussing the emerging concepts in stromal cell and ECM heterogeneity, stromal cell metabolism, early events in carcinogenesis involving contributions from tumor cells and their microenvironment, stress responses to oxygen and nutrient gradients, translational impact of targeting the microenvironment, tumor immunity and immunotherapy.”
http://www.aacr.org/Meetings/Pages/Program-Detail.aspx?EventItemID=73&DetailItemID=419
1-9-16 10:30am-12:45pm: Plenary Session 5: “Actions of Innate & Adaptive Immunity”
Chairperson: Joan Massague**, Memorial Sloan Kettering Inst.
1. Tak Mak, Univ./Toronto, “Beyond checkpoint blockade: Emerging strategies”
2. Elizabeth Jaffee, Johns Hopkins, “Tipping the balance from a procarcinogenic to...”
3. Jeffrey Molldrem, MD Anderson, “T cell receptor-like antibody 8F4 targets leukemia...”
4. Joan Massague, MSK-CC, “Latency & immune evasion of metastatic stem cells”
5. Rolf A. Brekken (PPHM SAB), UTSW-MC/Dallas, “Antibody mediated blockade of phosphatidylserine synergizes with immune checkpoint blockade by inhibiting multiple immune suppressive mechanisms”
..
..**Dr. Joan Massague is not just some doc from MSK, he is the DIRECTOR OF THE SLOAN KETTERING INSTITUTE and a very well-known scientist.
http://www.mskcc.org/research-areas/programs-centers/ski/director-joan-massague
Here is a video of Dr. Massague talking about the “Next Wave” of cancer research: https://www.mskcc.org/research-areas/programs-centers/ski..
..
..